Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Tardive dyskinesia: advances of modern pharmacogenetics

O.Yu. Fedorenko, S.A. Ivanova, A.V. Semke, N.A. Bokhan
Mental Health Research Institute, Tomsk NIMC

Abstract: Tardive dyskinesia (TD) is a serious irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. The main pharmacogenetic investigations of drug-induced TD are conducted to identify the association with gene polymorphism of xenobiotic metabolism system, neurotransmitter receptors and oxidative stress system. This review highlights recent advances in the pharmacogenetic investigation of TD in patients with schizophrenia, taking into account the clinical heterogeneity of this movement disorder. Modern pharmacogenetics is a promising tool for the development of personalized treatment technologies based on the genetic profile of the patient.

  • 1. Boiko A.S., Pozhidaev I.V., Cherevko N.A., Ivanova S.A. Polimorfizmy gena NMDA-retseptora u bol'nykh shizofreniei s tardivnoi diskeneziei // Fundamental'nye issledovaniya. – 2015. – № 1. – S. 231–234.
  • 2. Ivanova S.A., Boiko A.S., Fedorenko O.Yu., Shchigoreva Yu.G., Rudikov E.V., Borodyuk Yu.N., Semke A.V., Bokhan N.A. Polimorfizm gena fermenta glutation-S-transferazy i dvigatel'nye narusheniya u bol'nykh shizofreniei // Fundamental'nye issledovaniya. – 2013. – № 9. – S. 650–654.
  • 3. Ivanova S.A., Fedorenko O.Yu., Bokhan N.A., Boyarko E.G., Semke A.V., Sorokina V.A., Govorin N.V., Abramov D.E. Rol' polimorfizma gena dofaminovogo retseptora DRD3 v razvitii pozdnei diskinezii pri shizofrenii // Sotsial'naya i klinicheskaya psikhiatriya. – 2015. – T. 25, № 1 – S. 5–8.
  • 4. Ivanova S.A., Fedorenko O.Yu., Bokhan N.A., Lunen A. Farmakogenetika tardivnoi diskinezii. – Tomsk: Novye pechatnye tekhnologii, 2015. – 120 s.
  • 5. Ivanova S.A., Fedorenko O.Yu., Rudikov E.V., Semke A.V. Farmakogenetika pozdnei diskinezii // Sibirskii vestnik psikhiatrii i narkologii. – 2013. – T. 78, № 3. – S. 5–9.
  • 6. Ivanova S.A., Fedorenko O.Yu., Ryadovaya L.A., Kornetova E.G., Rudikov E.V., Semke A.V., Lunen A. Polimorfizmy genov neiromediatornogo obmena u bol'nykh shizofreniei s dvigatel'nymi rasstroistvami // Sibirskii vestnik psikhiatrii i narkologii. – 2009. – № 5. – S. 31–34.
  • 7. Ivanova S.A., Fedorenko O.Yu., Smirnova L.P., Semke A.V. Poisk biomarkerov i razrabotka farmakogeneticheskikh podkhodov k personalizirovannoi terapii bol'nykh shizofreniei // Sibirskii vestnik psikhiatrii i narkologii. – 2013. – № 1. – S. 12–16.
  • 8. Karlson A., Lekrub'e I., Mosolov S.N. Dofaminovaya teoriya patogeneza shizofrenii: rukovodstvo dlya vrachei. – London, 2004. – 176 s.
  • 9. Kornetova E.G., Boiko A.S., Borodyuk Yu.N., Semke A.V. Tardivnaya diskineziya u bol'nykh shizofreniei: klinika i faktory riska. – Tomsk: Novye pechatnye tekhnologii, 2014. – 106 s.
  • 10. Mosolov S.N. Sovremennaya antipsikhoticheskaya farmakoterapiya shizofrenii // Rus. med. zhurn. – 2004. – T. 12, № 10. – S. 646–652.
  • 11. Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / pod red. S.N. Mosolova. M., 2012. S. 11–61.
  • 12. Nasyrova R.F., Ivanov M.V., Neznanov N.G. Vvedenie v psikhofarmakogenetiku. – SPb: Izdat. tsentr SPb NIPNI im. V.M. Bekhtereva, 2015. – 272 s.
  • 13. Patent RF № 2447832, 15.12.2010. Ivanova S.A., Smirnova L.P., Semke A.V., Krotenko N.M., Rudikov E.V., Ivanova A.S., Kornetova E.G. Sposob prognozirovaniya riska razvitiya pozdnei diskinezii pri neirolepticheskoi terapii bol'nykh shizofreniei.
  • 14. Psikhofarmakologicheskie i protivoepilepticheskie preparaty, razreshennye k primeneniyu v Rossii / pod red. S.N. Mosolova. M.: Binom, 2004.
  • 15. Semke A.V., Vetlugina T.P., Rakhmazova L.D., Ivanova S.A., Schastnyi E.D., Fedorenko O.Yu., Lobacheva O.A., Gutkevich E.V., Kornetova E.G., Danilenko O.A.Biologicheskie i kliniko-sotsial'nye mekhanizmy razvitiya shizofrenii (itogi kompleksnoi temy NIR FGBU «NIIPZ» SO RAMN, 2009–2012 gg.) // Sibirskii vestnik psikhiatrii i narkologii. – 2013. – T. 79, № 4. – S. 18–25.
  • 16. Seredenin, S.B. Lektsii po farmakogenetike. – M.: MIA, 2004. – 303 s.
  • 17. Smirnova L.P., Krotenko N.V., Krotenko N.M., Loginov V.N., Dukhan M.V., Ivanova S.A., Mal'tseva Yu.L. Aktivnost' antioksidantnykh fermentov v eritrotsitakh bol'nykh psikhicheskimi i nevrologicheskimi rasstroistvami. Sibirskii vestnik psikhiatrii i narkologii. – 2008. – № 1. – S. 133–135.
  • 18. Standarty okazaniya pomoshchi bol'nym shizofreniei. Moskovskii NII psikhiatrii Roszdrava / pod red. V.N. Krasnova, I.Ya. Gurovicha, S.N. Mosolova, A.B. Shmuklera. – M., 2006. – 54 s.
  • 19. Sychev D.A., Ramenskaya G.V., Ignat'ev I.V., Kukes V.G. Klinicheskaya farmakogenetika / pod red. V.G. Kukesa, V.P. Bochkova. – M.: GEOTAR-Media, 2007. – 248 s.
  • 20. Psikhiatricheskaya pomoshch' bol'nym shizofreniei: klinicheskoe rukovodstvo / pod red. V.N. Krasnova, I.Ya. Gurovich, S.N. Mosolova i soavt. – M.: Medpraktika, 2007. – 260 s.
  • 21. Uzbekov M.G., Misionzhnik E.Yu., Shmukler A.B., Gurovich I.Ya., Gryzunov Yu.A., Smolina N.V., Kalinina V.V., Sokolova T.N., Moskvitina T.A., Shevchenko V.A. Aktivnost' monoaminoksidazy i pokazateli endogennoi intoksikatsii u bol'nykh s pervym epizodom shizofrenii // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. – 2009. – T. 109, № 5. – S. 48–52.
  • 22. Shchigoreva Yu.G., Boiko A.S., Krotenko N.M., Smirnova L.P., Kornetova E.G., Semke A.V., Ivanova S.A. Glutation kak kriterii prognoza riska lekarstvennoi pozdnei diskinezii u bol'nykh shizofreniei // Sibirskii vestnik psikhiatrii i narkologii. – 2012. – № 6. – S. 75–78.
  • 23. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice // Proc Natl Acad Sci USA. – 1996. – Vol. 93. – P. 1945–1949.
  • 24. Aquino C.C., Lang A.E. Tardive dyskinesia syndromes: current concepts // Parkinsonism and Related Disorders. – 2014. – Vol. 20, Suppl. 1. – S. 113–117.
  • 25. Al Hadithy A.F., Ivanova S.A., Pechlivanoglou P., Semke A., Fedorenko O., Kornetova E., Ryadovaya L., Brouwers J.R., Wilffert B., Bruggeman R., Loonen A.J. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress in neuro-psychopharmacology & biological psychiatry. – 2009. – Vol. 33, No. 3. – P. 475–481.
  • 26. Al Hadithy A.F.Y., Wilffert B., Brouwers J.R.B.J., Loonen A.J.M., Ivanova S.A., Semke A., Fedorenko O., Kornetova E., Ryadovaya L., Pechlivanoglou P. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, AND GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia // Human Psychopharmacology. – 2010. – Vol. 25, No. 1. – P. 84–91.
  • 27. Bakker P.R., Bakker E., Amin N., van Duijn C.M., van Os J., van Harten P.N. Candidate Gene-Based Association Study of Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients: A Prospective Study // PLoS One. – 2012. – Vol. 7, No. 5. – e36561.
  • 28. Bakker P.R., van Harten P.N., van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions // Molecular psychiatry. – 2008. – Vol. 13, No. 5. – P. 544–556.
  • 29. Basile V.S., Masellis M., Badri F., Paterson A.D., Meltzer H.Y., Lieberman J.A. et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia // Neuropsychopharmacology. – 1999. – Vol. 21, No. 1. – P. 17–27.
  • 30. Basile V.S., Ozdemir V., Masellis M. et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia // Molecular psychiatry. – 2000. – Vol. 5, No. 4. – P. 410–417.
  • 31. Calabrese V., Giordano J., Crupi R., Di Paola R., Ruggieri M., Bianchini R., Ontario M.L., Cuzzocrea S., Calabrese E.J. Hormesis, cellular stress response and neuroinflammation in schizophrenia: Early onset versus late onset state // J Neurosci Res. – 2016. – No. 11. – P. 1–12.
  • 32. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1-year studies // Am J Psychiatry. – 2004. – Vol. 161. – No. 3. – P. 414–425.
  • 33. Faurbye A., Rasch P.J., Petersen P.B., et al. Neurological symptoms in pharmacotherapy of psychoses // Acta Psychiatr Scand. – 1964. – Vol. 40. – P. 10–27.
  • 34. Fedorenko O.Y., Loonen A.J., Lang F., Toshchakova V.A., Boyarko E.G., Semke A.V., Bokhan N.A., Govorin N.V., Aftanas L.I., Ivanova S.A. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. // The International Journal of Neuropsychopharmacology. – 2015. – Vol. 18, No. 6. – P. 1–6.
  • 35. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation // Int Rev Psychiatry. – 2013. – Vol. 25, No. 5. – P. 534–553.
  • 36. Gunes A., Dahl M.L., Spina E., Scordo M.G. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients // Eur J Clin Pharmacol. – 2008. – Vol. 64, No. 5. – P. 477–482.
  • 37. Hsieh C.J., Chen Y.C., Lai M.S., Hong C.J., Chien K.L. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia // Psychiatry Res. – 2011. – Vol. 188, No. 1. – P. 175–176.
  • 38. Ivanova S.A., Al Hadithy A.F.Y., Brazovskaya N., Semke A., Wilffert B., Fedorenko O., Brouwers J.R.B.J., Loonen A.J.M. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia // Hum Psychopharmacol Clin Exp. – 2012. – Vol. 27. – P. 334–337o
  • 39. Ivanova S.A., Filipenko M.L., Vyalova N.M., Voronina E.N., Pozhidaev I.V., Osmanova D.Z., Ivanov M.V., Fedorenko O.Y., Semke A.V., Bokhan N.A. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects // Bull Exp Biol Med. – 2016. – Vol. 160, No. 5. – P. 687–690.
  • 40. Ivanova S.A., Loonen A.J., Bakker P.R., Freidin M.B., Ter Woerds N.J., Al Hadithy A.F., Semke A.V., Fedorenko O.Y., Brouwers J.R., Bokhan N.A., van Os J., van Harten P.N., Wilffert B. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations // SAGE Open Med. – 2016. – 4:2050312116643673. – DOI: 10.1177/2050312116643673. – eCollection 2016.
  • 41. Ivanova S.A., Loonen A.J., Pechlivanoglou P., Freidin M.B., Al Hadithy A.F., Rudikov E.V., Zhukova I.A., Govorin N.V., Sorokina V.A., Fedorenko O.Y., Alifirova V.M., Semke A.V., Brouwers J.R., Wilffert B. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia // Transl Psychiatry. – 2012. – Vol. 2. – e67.
  • 42. Ivanova S.A., Toshchakova V.A., Filipenko M.L., Fedorenko O.Y., Boyarko E.G., Boyko A.S., Semke A.V., Bokhan N.A., Aftanas L.I., Loonen A.J.M. Cytochrome P450 1A2 gene polymorphism may diminish tardive dyskinesia by increased inducibility // The World Journal of Biological Psychiatry. – 2015. – Vol. 16, No. 3. – P. 200–205.
  • 43. Janno S., Holi M., Tuisku K., Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients // Am J Psychiatry. – 2004. – Vol. 161, No. 1. – P. 160–163.
  • 44. Kling-Petersen T., Ljung E., Svensson K. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain // J Neural Transm Gen Sect. – 1995. – Vol. 102. – P. 209–220.
  • 45. Knol W., van Marum R.J., Jansen P.A., Strengman E., Al Hadithy A.F., Wilffert B., Schobben A.F., Ophoff R.A., Egberts T.C. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach // J Clin Psychopharmacol. – 2013. – Vol. 33, No. 3. – P.405–410.
  • 46. Koning J.P., Vehof J., Burger H., Wilffert B., Al Hadithy A., Alizadeh B., van Harten P.N., Snieder H. Genetic Risk and Outcome in Psychosis (GROUP) investigators.. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients // Psychopharmacology (Berl). – 2012. – Vol. 219. – No. 3. – P. 727–736.
  • 47. Kropp S., Kern V., Lange K. et al. Oxidative stress during treatment with first- and second-generation antipsychotics // J Neuropsychiatry Clin Neurosci. – 2005. – Vol. 17. – P. 227–231.
  • 48. Lanning R.K., Zai C.C., Müller D.J. Pharmacogenetics of tardive dyskinesia: an updated review of the literature // Pharmacogenomics. – 2016. – Vol. 17, No. 12. – P. 1339–1351.
  • 49. Lattuada E., Cavallaro R., Serretti A. et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment // Internat J Neuropsychopharmacology. – 2004. – Vol. 7, No. 4. – P. 489–493.
  • 50. Lee H.J., Kang S.G. Genetics of tardive dyskinesia // Int Rev Neurobiol. – 2011. – Vol. 98. – P. 231–264.
  • 51. Lencz T., Malhotra A. K. Pharmacogenetics of antipsychotic side effects // Dialogues in Clinical Neuroscience. – 2009. – Vol. 11, No. 4. –P. 405–415.
  • 52. Lerer B., Segman R. H., Tan E. C. et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype // Internat J Neuropsychopharmacology. – 2005. – Vol. 8, No. 3. – P. 411–425.
  • 53. Lerner P.P., Miodownik C., Lerner V. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management // Psychiatry Clin Neurosci. – 2015. – Vol. 69, No. 6. – P. 321–334.
  • 54. Loonen A.J., Ivanova S.A. New insights into the mechanism of drug-induced dyskinesia // CNS Spectrums. – 2013. – Vol. 18, No. 1. – P. 15–20.
  • 55. Loonen A.J.M., van Praag H.M. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard // Journal of Clinical Psychopharmacology. – 2007. – Vol. 27, No. 5. – P. 423–430.
  • 56. Loonen A.J.M., Ivanova S.A. Role of 5-HT2C receptors in dyskinesia // International Journal of Pharmacy and Pharmaceutical Sciences – 2016. – Vol. 8, No. 1. – P. 5–10.
  • 57. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system // Biochem Biophys Res Commun. – 1996. – Vol. 225. – P. 1068–1072.
  • 58. Maric N.P., Jovicic M.J., Mihaljevic M., Miljevic C. Improving Current Treatments for Schizophrenia // Drug Dev Res. – 2016. – Vol. 77, No. 7. – P. 357–367.
  • 59. Meador-Woodruff J.H., Haroutunian V., Powchik P., Davidson M., Davis K.L.,Watson S.J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex // Arch Gen Psychiatry. – 1997. – Vol. 54. – P. 1089–1095.
  • 60. Moore T.J., Furberg C.D. The Harms of Antipsychotic Drugs: Evidence from Key Studies // Drug Saf. – 2017. – Vol. 40, No. 1. – P. 3–14.
  • 61. Müller D.J., Chowdhury N.I., Zai C.C. The pharmacogenetics of antipsychotic-induced adverse events // Curr Opin Psychiatry. – 2013. – Vol. 26, No. 2. – P. 144–150.
  • 62. Müller D.J., Kekin I., Kao A.C., Brandl E.J. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic // Int Rev Psychiatry. – 2013. – Vol. 25, No. 5. – P. 554–571.
  • 63. O'Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis // Int J Geriatr Psychiatry. – 2016. – Vol. 31, No. 7. – P. 683–693.
  • 64. Ozdemir V., Basile V.S., Masellis M., Kennedy J.L. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes // J Biochem Biophys Methods. – 2001. – Vol. 47, No. 1–2. – P. 151–157.
  • 65. Park Y.M., Kang S.G., Choi J.E., Kim Y.K., Kim S.H., Park J.Y., Kim L., Lee H.J. No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients // Psychiatry Investig. – 2011. – Vol. 8, No. 1. – P. 49–54.
  • 66. Reynolds G.P. Receptor mechanisms in the treatment of schizophrenia // J Psychopharmacol. – 2004. – No. 18. – P. 340–345.
  • 67. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen // Nervenarzt. – 1957. – Vol. 28, No. 12. – P. 550–553.
  • 68. Segman R.H., Heresco-Levy U., Finkel B., Inbar R., Neeman T., Schlafman M., Dorevitch A., Yakir A., Lerner A., Goltser T., Shelevoy A., Lerer B. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2C and DRD3 alleles to susceptibility // Psychopharmacology. – 2000. – Vol. 152, No. 4. – P. 408–413.
  • 69. Shamy M.C., Zai C., Basile V.S., Kennedy J.L., Müller D.J., Masellis M. Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor // Curr Pharmacogenomics Person Med. – 2011. – Vol. 9, No. 2. – P. 94–101.
  • 70. Sigwald J., Bouttier D., Raymondeaud C. et al. 4 Cases of faciobucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics // Rev Neurol (Paris). – 1959. – Vol. 100. – P. 751–755.
  • 71. Steen V.M., Løvlie R., MacEwan T., McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients // Mol Psychiatry. – 1997. – Vol. 2, No. 2. – P. 139–145.
  • 72. Sullivan L.C., Clarke W.P., Berg K.A. Atypical antipsychotics and inverse agonism at 5-HT2 receptors // Curr Pharm Des. – 2015. – Vol. 21, No. 26. – P. 3732–3738.
  • 73. Suzuki M., Hurd Y.L., Sokoloff P., Schwartz J.C., Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain // Brain Res. – 1988. – Vol. 779. – P. 58–74.
  • 74. Tarsy D., Baldessarini R.J. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? // Mov Disord. – 2006. – Vol. 21, No. 5. – P. 589–598.
  • 75. Tenback D.E., van Harten P.N. Epidemiology and risk factors for (tardive) dyskinesia // International Review of Neurobiology. – 2011. – Vol. 98. – P. 211–230.
  • 76. Tsai H.T., Caroff S.N., Miller del D. et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet. – 2010. – Vol. 153B, No. 1. – P. 336–340.
  • 77. Tsai H.T., North K.E., West S.L., et al. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis // Am J Med Genet B Neuropsychiatr Genet. – 2010. – Vol. 153B, No. 1. – P. 57–66.
  • 78. Wilffert B., Al Hadithy A.F., Sing V.J., Matroos G., Hoek H.W., van Os J., Bruggeman R., Brouwers J.R., van Harten P.N. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX // J Psychopharmacol. – 2009. – Vol. 23, No. 6. – P. 652–659.
  • 79. Zai C.C., De Luca V., Hwang R.W. et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients // Molecular psychiatry. – 2007. – Vol. 12, No. 9. – P. 794–795.
  • 80. Zai C.C., Tiwari A.K., Basile V. et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes // Progress in neuro-psychopharmacology & biological psychiatry. – 2010. – Vol. 34, No. 1. – P. 50–56.
  • 81. Zhang Z., Hou G., Zhang X., Yao H., Sha W., Zhang X. Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val) // Zhonghua Yi Xue Yi Chuan Xue Za Zhi. – 2003. – Vol. 20, No. 2. – P. 98–102.
  • 82. Zhang J.P., Malhotra A.K. Pharmacogenetics and Antipsychotics: Therapeutic Efficacy and Side Effects Prediction // Expert Opin Drug Metab Toxicol. – 2011. – Vol. 7, No. 1. – P. 9–37.